oral glp-1 drugs in development Trends the of Receptor Agonists Four oral GLP-1R products in
Description
Lower risks for AF associated with GLP-1RA were consistently observed in subgroups by baseline age, sex, race, BMI, and HbA1c
Design, synthesis, structure-activity relationships, and docking studies of 1-(gamma-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors
Mancini GBJ, Maron DJ, Hartigan PM, et al
What this means for the stock In March, Eli Lilly unveiled promising phase 3 clinical trial data for retatrutide
But still fascinating to see
